S. Peter Ludwig is a senior principal in the New York office of Fish & Richardson P.C. Mr. Ludwig’s practice is focused on patent counseling, and portfolio management, patent prosecution, as well as litigation, licensing, and due diligence. Mr. Ludwig has companies and academic institutions in the life science, chemical and medical device fields. His experience includes work in the fields of biotechnology (vaccines, functional genomics, pharmacogenomics, high throughput screening, stem cell technology, gene therapy), pharmaceuticals (neuroleptic drugs, drug delivery systems, anti-metabolites, natural pharmaceuticals, anti-tumor agents, anti-viral agents), medical devices, photo-chemistry, paper chemistry, medical rubber products, aluminum processing and diagnostic products.
Mr. Ludwig has spoken on intellectual property issues for numerous professional associations, including the American Chemical Society, Pharmaceutical Research and Manufacturers of America, the New York Biotechnology Association, the Association of the Bar of the City of New York, the Biotechnology Industry Association, the Genetics Policy Institute, The American Conference Institute and the New York Intellectual Property Law Association.
Under an Ampart grant from the U.S. State Department, Mr. Ludwig lectured and advised government authorities and industry representatives in Brazil on strengthening intellectual property rights for biotechnology and pharmaceuticals.
From 2001 to 2005, Mr. Ludwig served as a speaker and as the chair or co-chair of the annual biotechnology and pharmaceutical law and business program sponsored by the Practising Law Institute in New York and San Francisco. Mr. Ludwig was the chair of the New York Intellectual Property Law Association’s patentable subject matter committee for the 2009-2010 term.
Process Patents are Vital in Biotech-Why Not Extend Them? (S. Peter Ludwig and Brian Coggio) IP Law 360 August 10, 2015
“Life Sciences Update – Spring 2012” (S. Peter Ludwig, et al.)
“Stem Cell Law, Regulation and Intellectual Property: A Fundamental Pillar of Success” World Stem Cell Report 2009 (S. Peter Ludwig, Samuel Woodley, Ph.D.)
“Potholes & Roadblocks on the Road to Patent Protection” Medical Innovations & Business, pp. 12-19, October 2009 (S. Peter Ludwig, Andrew K. Holmes, Ph.D.)
“Generic Drug-Approval Process: Hatch-Waxman Update” Chapter in The Pharmaceutical Regulatory Process Second Edition, I. Berry, Editor (2008) (S. Peter Ludwig, Marc Gross)
Biotechnology and Pharmaceutical Patents: Law and Practice, 2008, Aspen Publishers (Marc Gross, S. Peter Ludwig, Robert Sullivan)
Biotechnology and Pharmaceutical Patents, Law and Practice, 2007, Aspen Publishers (S. Peter Ludwig, Robert C. Sullivan, Marc Gross)
“Hatch-Waxman in the Federal Courts: From 1994-2004″ Drug Development and Industrial Pharmacy, 31(2): 15-22, (2005) (S. Peter Ludwig, Kristin B. Kosinski)
“Generic Drug Approval Process: Post 1984: Hatch-Waxman Reform” Chapter in Introduction to the Pharmaceutical Regulatory Process, I. Berry, Editor (2005) (S. Peter Ludwig, Marc Gross, Atul Singh, Kristin B. Kosinski)
“Patents and Polymorphs” Chapter in Biotechnology and Pharmaceutical Law 2004: Patents and Business Strategies, Practising Law Institute Intellectual Property Course Handbook Series (S. Peter Ludwig, Kristin B. Kosinski)
“Patenting Life Forms” Chapter in Biotechnology Law 2003: Biotechnology Patents & Business Strategies, Practising Law Institute Intellectual Property Course Handbook Series (S. Peter Ludwig, Samuel Woodley, Ph.D., Sandra Lee)
“No room for experiment: The Federal Circuit’s Narrow Construction of the Experimental Use Defense” Nature Biotechnology 21:453, April 2003 (S. Peter Ludwig, Jason C. Chumney)
“Preparing Legal Opinions for Biotechnology Patents” Biotechnology Law 2002: Biotechnology Patent & Business Strategies (S. Peter Ludwig, John Todaro, Sandra Lee)
“Life After Eli Lilly: Planning for Compliance with the Written Description Requirement” Chapter in Biotechnology Law 2001: Biotechnology Patents & Business Strategies in the New Millennium, Practising Law Institute Intellectual Property Course Handbook Series (S. Peter Ludwig, Samuel Woodley, Ph.D.)
“Inadvertent Disclosure of Privileged Information” New York Law Journal, October 18, 1999, pp. 6, 14-15 (S. Peter Ludwig, Patricia J. Clarke, T. David Bomzer)
Recognized as a World Intellectual Property Review Leader (2021).
Selected by Super Lawyers New York (2016 and 2019).
Recognized as a 2013 Top Rated – AV® PreeminentTM Lawyers in Intellectual Property Law.
- IP Licensing, Transactions, and Agreements
- Opinions and Strategic Counseling
- Patent Prosecution
- Patent Litigation
LL.M., Trade Regulation, New York University (1972)
J.D., St. John's University School of Law (1968)
B.A., Biology, New York University (1964) Attended biochemistry classes in M.S. program
- U.S. Patent and Trademark Office 1970
- New York 1969
- Supreme Court of the United States
- U.S. Court of Appeals for the Federal Circuit
- U.S. District Court for the Eastern District of New York
- U.S. District Court for the Southern District of New York
January 24th, 2018 | 11:30 am EST
2018 World Stem Cell Summit
December 7th, 2016 | 2:00 pm EST
2016 World Stem Cell Summit
December 10th, 2015 | 7:30 am EST
2015 World Stem Cell Summit
November 12th, 2015
IPR and Subject Matter Eligibility at the USPTO
August 12, 2015
"Process Patents Are Vital In Biotech — Why Not Extend Them?"
May 29th, 2013
NYBA 22nd Annual Meeting
December 3rd, 2012
World Stem Cell Summit 2012
April 27th, 2010 | 7:30 am EDT
World Research Group "Second Annual Corporate IP Counsel Summit"
January 2nd, 2011
What Israeli Companies Really Need To Know About IP Protection and Enforcement in the U.S.
October 3rd, 2011
2011 World Stem Cell Summit
September 12th, 2010 | 8:00 am EDT
Rodman & Renshaw Annual Global Investment Conference, 12th Annual Healthcare Conference
November 30th, 2011
13th Advanced Forum on Biotech Patents